Rivals may burst shares frenzy for weight-loss drug firm Novo  

Wweight loss drug Wegovy is made by Denmark's Novo Nordisk.

A frenzy around obesity drugs made Novo Nordisk Europe’s biggest stock-market success story of 2023, but repeating the trick won’t be so easy.

Shares of Novo, which makes the diabetes drug Ozempic and weight loss medicine Wegovy, have risen 42% this year, as investors latched on to the growth potential of a market that some analysts predict could reach $100bn by 2030.